HOME >> BIOLOGY >> NEWS
Putting randomness to work: unique form of nanoscale random motion may drive key cellular functions

of a phosphate -- releases from the microtubule.
  • ATP hydrolysis makes the switch mechanism irreversible. Though ATP normally provides energy for macromolecular synthesis, Fox argues that in motor proteins ATP performs a switching role, changing the protein conformation and its binding affinity.
  • The unbound head -- just 5-7 nanometers in diameter -- is moved about randomly by Brownian motion in the cellular fluid until it encounters a new site where it can bind. Reported in the early 1800s by biologist Robert Brown, Brownian motion is the irregular activity of tiny particles suspended in a fluid. It results from the thermally driven movement of molecules in a fluid, the velocity of the particles depending on the temperature temperature.
  • Because of structural limits in the kinesin and spacing of binding sites on the microtubules, the moving head can reach only one possible binding site -- 8 nanometers past the bound head, which temporarily remains attached to the microtubule.
  • The head binds to the new site, moving the kinesin and its cargo about 8 nanometers along the microtubule.
  • The process quickly starts anew with the original two heads in interchanged positions.
  • "Normally, Brownian motion cannot do anything concerted or with directionality, because it is random," Fox explained. "But what happens here is a random process in a system that has asymmetric boundary conditions created by the ATP switching. That makes it possible to get a net directed motion along the microtubule."

    The model described by Fox and post-doctoral colleague Mee Hyang Choi depends on two unique properties of structures at the nanometer-scale: thermal energy can be a robust source of power, and random motion occurs very rapidly.

    "Normally, we would t
    '"/>

    Contact: John Toon
    john.toon@edi.gatech.edu
    404-894-6986
    Georgia Institute of Technology Research News
    3-Jun-2001


    Page: 1 2 3 4

    Related biology news :

    1. Putting energy into heart protection
    2. Putting GPS to work, researchers shed light on road-following by pigeons
    3. Putting genes in a pill
    4. Putting microRNAs in their place
    5. Putting muscle in the nucleus
    6. Putting muscle in the nucleus
    7. Putting a price tag on paradise
    8. Putting medical research on-line to give patients the information they need
    9. Putting Doesnt Pollute, Research Finds
    10. Putting A Price Tag On Pollution
    11. Putting Down Your Roots: How Plants Know To Do It

    Post Your Comments:
    (Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
    (Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
    (Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
    Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
    (Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
    (Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
    (Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
    (Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
    Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
    Cached News: